Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
CREO MEDICAL GROUP PLC LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.50p -3.59% 174.50p 172.00p 177.00p 181.00p 171.00p 181.00p 14,018 15:59:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -8.9 -13.0 - 209.27

CREO MEDICAL Share Discussion Threads

Showing 1226 to 1245 of 1250 messages
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
DateSubjectAuthorDiscuss
22/10/2018
10:29
Creo Medical‏ @CreoMedical · 17 minutes ago Hello from UEG Week Vienna! Come and visit us Booth 14, Hall x3 to see the device that one clinician called “the holy grail of therapeutic endoscopy!” #uegweek
someuwin
19/10/2018
15:47
Anyone go to the presentation? Any feedback? What is their IP they hold as this is key to others entering the market.
nimbo10
19/10/2018
15:24
Yeah it's a bit of a winner in terms of an investment case. I did some research a while ago into competition and I did find some (a Johnson & Johnson owned company called Ethicon has a microwave ablation machine) but CREO does seem to have a massive headstart in the GI tract area. If they can start showing the benefits of the products with lung cancer and other tumours then that would present a huge opportunity.
dplewis1
19/10/2018
15:11
The Investor's Presentation is almost too good to believe. Is there a catch? So far ~50 human procedures so absolutely ground zero for the products. 187 worldwide patents with 385 patents pending. Global market around $3Bn. They look like an experienced team. Plus scope (pardon the pun) to get into pancreatic and lung cancers. And they claim minimal competition.
drbob_ceng
19/10/2018
06:19
Also the slides are available from Wednesday:http://investors.creomedical.com/investors/reports-and-presentations/2018Slide 5 very good for a facts and figures overview. Impressive stuff.
dplewis1
18/10/2018
07:45
Cenkos today "Creo Medical Group Plc Commercial progress Creo Medical has announced its first mainland Europe distribution agreements covering Spain, the Netherlands, Belgium and Luxemburg. These announcements follow similar agreements covering the UK, South Africa and Asia-Pacific and further demonstrate the progress which Creo is making on the commercial front. We maintain our Buy recommendation."
someuwin
17/10/2018
14:30
It dropped from 8 quid to 1 quid I think I might give that a swerve..
dplewis1
17/10/2018
13:47
You wanna look at Farn :)
toffeeman
17/10/2018
11:19
So it's not amazing news :)
toffeeman
17/10/2018
10:25
Yes pretty much priced in. Still an all round confidence builder though as they deliver on their strategy repeatedly
dplewis1
17/10/2018
09:28
I would have thought that the real news would have been if they were not securing distribution! Surely this is as expected?
toffeeman
17/10/2018
08:19
Yup - no reason these products can't be rolled out worldwide. Better results. Quicker. More cost effective etc.
someuwin
17/10/2018
06:11
RNS.. that's amazing news. Developed markets in Europe are huge for med tech products, this appears to be going global.
dplewis1
02/10/2018
07:17
Can buy £2k online. But not £3k. So stock supply is still tight.
someuwin
01/10/2018
15:33
Crikey. Every time I check in on this one it's gone up again..what a fantastic share
dplewis1
01/10/2018
11:32
Can't get a buy quote for just £1k
someuwin
01/10/2018
07:08
Up and running.
someuwin
28/9/2018
15:42
CREO clearly has a huge opportunity in a multi £billion market. The Group also appears to have made plenty of progress since arriving on AIM in December 2016 at a share price of 76p and market capitalisation of a modest £61m, reflected in the 200% rise in share price to 228p.
investorschampion
28/9/2018
09:17
Part of Cenkos note today... "Creo Medical Group Plc Momentum continues to build Creo Medical has announced its interim results to 30 June 2018. Undoubtedly this has been a strong period for the company with its lead product having been used clinically outside of the UK for the first time. Additionally, framework distribution agreements have been completed in the UK and South Africa and with Pentax in Asia-Pacific and 45 clinicians have been successfully trained as of 28 August 2018. Post-period end the company successfully raised £48.5m (gross) in an oversubscribed placing. We maintain our Buy recommendation."
someuwin
28/9/2018
07:21
All going to plan... Craig Gulliford, Chief Executive Officer, commented: "We continue to make good progress against our strategic objectives, executing on our training led commercialisation plan, targeting selected clinicians and key opinion leaders to drive clinical adoption. As of 28 August 2018, 45 clinicians have been successfully trained. Significantly, a growing number of patients in the UK are being successfully treated using the Speedboat device powered by our CROMA platform. Post period-end we have shipped our first products to South Africa which have been used in seven procedures so far. Furthermore, with the extension of our agreement with Hoya Group, Pentax Medical we expect to ship our first products to the APAC region in the upcoming months. We continue to invest in our pipeline, positioning us well to become a leading advanced energy, minimally invasive, medical device company. We remain on track for full commercial launch in 2019, and following the placing, are well funded to achieve our goals."
someuwin
Chat Pages: 50  49  48  47  46  45  44  43  42  41  40  39  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20181121 20:20:31